Accelr8 Announces Preliminary Earnings Report
August 19 2010 - 7:00AM
Business Wire
Accelr8 Technology Corporation (NYSE Amex: AXK) announced
its un-audited preliminary earnings report for the fiscal year
ended July 31, 2010. For the fiscal year, net sales revenues
totaled an estimated $2,223,254; net income from continuing
operations is estimated as $609,721 with total net income of
$650,447. For the previous year, net sales were $1,269,886 with a
loss from continuing operations of $(679,119) and a total net loss
of $(714,197). Shareholders’ equity totaled an estimated $4,900,463
for the most recent fiscal year, up from $3,894,494 at the end of
the previous fiscal year.
Based upon these un-audited results, the applicable Amex listing
requirement is $4 million in shareholders’ equity. These estimates
are subject to adjustment upon completion of the company’s annual
audit and filing of the annual report on Form 10-K.
About Accelr8
Accelr8 Technology Corporation (www.accelr8.com) is a developer of
innovative materials and instrumentation for advanced applications
in medical instrumentation, basic research, drug discovery, and
bio-detection. Accelr8 is developing a rapid analytical platform
for infectious pathogens, the BACcel™ system, based on its
innovative surface coatings, assay processing, and detection
technologies. In addition, Accelr8 licenses certain of its
proprietary technology for use in applications outside of Accelr8’s
own products.
Certain statements in this news release may be “forward-looking
statements” within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended. Statements regarding future prospects and
developments are based upon current expectations and involve
certain risks and uncertainties that could cause actual results and
developments to differ materially from the forward-looking
statement, including those detailed in the company's filings with
the Securities and Exchange Commission. Accelr8 does not undertake
an obligation to publicly update or revise any forward-looking
statements, whether as a result of new information or future
events.
Accelr8 (AMEX:AXK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Accelr8 (AMEX:AXK)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Accelerate Diagnostics, Inc. (American Stock Exchange): 0 recent articles
More Accelr8 Technology Corp. News Articles